Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models.

Ng SY, Yoshida N, Christie AL, Ghandi M, Dharia NV, Dempster J, Murakami M, Shigemori K, Morrow SN, Van Scoyk A, Cordero NA, Stevenson KE, Puligandla M, Haas B, Lo C, Meyers R, Gao G, Cherniack A, Louissaint A Jr, Nardi V, Thorner AR, Long H, Qiu X, Morgan EA, Dorfman DM, Fiore D, Jang J, Epstein AL, Dogan A, Zhang Y, Horwitz SM, Jacobsen ED, Santiago S, Ren JG, Guerlavais V, Annis DA, Aivado M, Saleh MN, Mehta A, Tsherniak A, Root D, Vazquez F, Hahn WC, Inghirami G, Aster JC, Weinstock DM, Koch R.

Nat Commun. 2018 May 22;9(1):2024. doi: 10.1038/s41467-018-04356-9.

2.

Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia.

Carvajal LA, Neriah DB, Senecal A, Benard L, Thiruthuvanathan V, Yatsenko T, Narayanagari SR, Wheat JC, Todorova TI, Mitchell K, Kenworthy C, Guerlavais V, Annis DA, Bartholdy B, Will B, Anampa JD, Mantzaris I, Aivado M, Singer RH, Coleman RA, Verma A, Steidl U.

Sci Transl Med. 2018 Apr 11;10(436). pii: eaao3003. doi: 10.1126/scitranslmed.aao3003.

3.

Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy.

Chang YS, Graves B, Guerlavais V, Tovar C, Packman K, To KH, Olson KA, Kesavan K, Gangurde P, Mukherjee A, Baker T, Darlak K, Elkin C, Filipovic Z, Qureshi FZ, Cai H, Berry P, Feyfant E, Shi XE, Horstick J, Annis DA, Manning AM, Fotouhi N, Nash H, Vassilev LT, Sawyer TK.

Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):E3445-54. doi: 10.1073/pnas.1303002110. Epub 2013 Aug 14.

4.

Use of coated capillaries for the electrophoretic separation of stereoisomers of a growth hormone secretagogue.

Nehmé R, Perrin C, Guerlavais V, Fehrentz JA, Cottet H, Martinez J, Fabre H.

Electrophoresis. 2009 Nov;30(21):3772-9. doi: 10.1002/elps.200900093.

PMID:
19810026
5.

Formation of multiple complexes between beta-dystroglycan and dystrophin family products.

Royuela M, Chazalette D, Hugon G, Paniagua R, Guerlavais V, Fehrentz JA, Martinez J, Labbe JP, Rivier F, Mornet D.

J Muscle Res Cell Motil. 2003;24(7):387-97.

PMID:
14677641
6.

Growth hormone secretagogues: past, present and future.

Fehrentz JA, Martinez J, Boeglin D, Guerlavais V, Deghenghi R.

IDrugs. 2002 Aug;5(8):804-14.

PMID:
12802697
7.

Dystrophin and dystrophin-associated protein in muscles and nerves from monkey.

Royuela M, Chazalette D, Rivier F, Hugon G, Paniagua R, Guerlavais V, Fehrentz JA, Martinez J, Mornet D.

Eur J Histochem. 2003;47(1):29-38.

PMID:
12685555
8.

New active series of growth hormone secretagogues.

Guerlavais V, Boeglin D, Mousseaux D, Oiry C, Heitz A, Deghenghi R, Locatelli V, Torsello A, Ghé C, Catapano F, Muccioli G, Galleyrand JC, Fehrentz JA, Martinez J.

J Med Chem. 2003 Mar 27;46(7):1191-203.

PMID:
12646029
9.

EP1572: a novel peptido-mimetic GH secretagogue with potent and selective GH-releasing activity in man.

Broglio F, Boutignon F, Benso A, Gottero C, Prodam F, Arvat E, Ghè C, Catapano F, Torsello A, Locatelli V, Muccioli G, Boeglin D, Guerlavais V, Fehrentz JA, Martinez J, Ghigo E, Deghenghi R.

J Endocrinol Invest. 2002 Sep;25(8):RC26-8.

PMID:
12240910

Supplemental Content

Loading ...
Support Center